Vorasidenib for IDH-mutant Grade 2 glioma
Treatments studied
Part of Cancer clinical trials.
This trial tests the drug vorasidenib for people with a slow-growing brain tumor (Grade 2 glioma) that has an IDH mutation. The goal is to see how well the drug works and how it affects your quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a slow-growing brain tumor called a Grade 2 astrocytoma or oligodendroglioma.
- Your tumor has an IDH1 or IDH2 mutation (a specific genetic change).
- You have already had surgery to remove or biopsy the tumor.
- Your doctor has decided that you do not need radiation or chemotherapy right now, and that vorasidenib is a good option for you.
- You are willing to fill out questionnaires about your well-being in German.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted drug, vorasidenib, for people with a specific type of slow-growing brain tumor (low-grade glioma) that has come back or is still present after surgery. The drug is guided by a special PET scan to see if it reaches the tumor.
This study asks patients with a specific type of low-grade brain tumor (IDH mutant grade 2 glioma) to share their experiences and quality of life while receiving a treatment called vorasidenib, with or without radiation. Your feedback helps doctors understand how well the treatment works from your perspective.
This study tests a new drug called safusidenib for people with IDH1-mutant gliomas (a type of brain tumor) that kept growing even while on the previous drug vorasidenib. The goal is to see if it can control the tumor safely and effectively.
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
This trial tests a new drug called BI 764532 for people with a type of brain tumor called glioma that has not gotten better with standard treatments. The drug targets a protein on the tumor cells, which might help stop the tumor from growing.
This study is looking at how well the drug ivosidenib works for people with a certain type of bile duct cancer (cholangiocarcinoma) that has a specific change in the IDH1 gene. It is for people whose cancer has spread or cannot be removed by surgery and who have already tried at least one other cancer treatment.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.